For individuals diagnosed with advanced NSCLC lacking driver mutations, the administration of anlotinib in conjunction with PD-1/PD-L1 inhibitors is considered a viable alternative treatment choice for later stages of the disease, and it has demonstrated noteworthy therapeutic efficacy [21, 22]. The gene discussed is CD274; the disease is non-small cell lung carcinoma.